HMDCF — HUTCHMED (China) Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1648257 ·
Hong Kong
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,753,097,000 | 71,330,000 | 501,835,000 |
| Jun 2025 | — | — | — | — | 1,775,940,000 | — | — |
| Dec 2024 | — | — | — | — | 1,274,196,000 | 153,958,000 | 502,343,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,643,000
Inventory
$41,129,000
Receivables
—
ST Investments
$1,295,945,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$549,121,984
EBITDA
$-20,515,000
Free Cash Flow
$-18,880,250
Enterprise Value
$609,436,992
Total Cash
$1,376,455,936
Total Debt
$94,508,000
Shares Out
869,070,839
Trailing EPS
$0.02
Book Value
$1.45
ROE
1.5%
ROA
-1.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 548,512,000 | -35,700,000 | 456,909,000 | 1,753,097,000 | 501,835,000 | 1,237,926,000 | -64,657,000 |
| Dec 2024 | 630,201,000 | -40,610,000 | 37,729,000 | 1,274,196,000 | 502,343,000 | 759,929,000 | 497,000 |
| Dec 2023 | 837,999,000 | 21,509,000 | 100,780,000 | 1,279,773,000 | 536,386,000 | 730,541,000 | 219,258,000 |
| Dec 2022 | 426,409,000 | -406,259,000 | -360,835,000 | 1,029,445,000 | 392,575,000 | 610,367,000 | -268,599,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
2026-09-28 00:00 · Yahoo
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
2026-09-24 20:59 · Yahoo
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
2026-09-24 00:00 · Yahoo
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
2026-09-03 17:02 · Yahoo
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
2026-09-03 09:30 · Yahoo
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
2026-09-03 07:27 · Yahoo
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
2026-09-03 04:00 · Yahoo
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in C
2026-08-31 00:00 · Yahoo
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
2026-08-28 00:00 · Yahoo
HUTCHMED shares rise as lung cancer drug trial hits key targets
2026-08-17 14:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.